An update on treatments and outcomes in peripartum cardiomyopathy

Richard Sheppard, Navin Rajagopalan, Jordan Safirstein, Joan Briller

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Peripartum cardiomyopathy (PPCM) is a well-established complication of pregnancy. Criteria include heart failure that presents with reduced left ventricular function, signs and symptoms of heart failure either late in pregnancy or early in the postpartum period. The incidence varies widely depending geography and ethnicity. The pathophysiology of PPCM is still an area of active investigation, but includes immune and inflammatory mechanisms, which are the subject of several investigations. Therapies for chronic heart failure from PPCM are similar to those patients with nonischemic cardiomyopathy from different etiologies, however novel therapies may include bromocriptine, pentoxifylline or other potential therapies influencing the immune system. The need for implantable defibrillators, left ventricular assist devices and cardiac transplant in women with PPCM is rare, and prognosis is better than other forms of nonischemic cardiomyopathy. Despite this, further information about the epidemiology, prognosis and potential therapies are required to better manage and diagnose PPCM in women with signs and symptoms of heart failure.

Original languageEnglish (US)
Pages (from-to)435-447
Number of pages13
JournalFuture Cardiology
Volume10
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Peripartum Period
Cardiomyopathies
Heart Failure
Signs and Symptoms
Pentoxifylline
Geography
Heart-Assist Devices
Bromocriptine
Pregnancy Complications
Implantable Defibrillators
Therapeutics
Left Ventricular Function
Postpartum Period
Immune System
Epidemiology
Transplants
Pregnancy
Incidence

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Sheppard, Richard ; Rajagopalan, Navin ; Safirstein, Jordan ; Briller, Joan. / An update on treatments and outcomes in peripartum cardiomyopathy. In: Future Cardiology. 2014 ; Vol. 10, No. 3. pp. 435-447.
@article{fdb90cdd9a264d19a11e283897a31814,
title = "An update on treatments and outcomes in peripartum cardiomyopathy",
abstract = "Peripartum cardiomyopathy (PPCM) is a well-established complication of pregnancy. Criteria include heart failure that presents with reduced left ventricular function, signs and symptoms of heart failure either late in pregnancy or early in the postpartum period. The incidence varies widely depending geography and ethnicity. The pathophysiology of PPCM is still an area of active investigation, but includes immune and inflammatory mechanisms, which are the subject of several investigations. Therapies for chronic heart failure from PPCM are similar to those patients with nonischemic cardiomyopathy from different etiologies, however novel therapies may include bromocriptine, pentoxifylline or other potential therapies influencing the immune system. The need for implantable defibrillators, left ventricular assist devices and cardiac transplant in women with PPCM is rare, and prognosis is better than other forms of nonischemic cardiomyopathy. Despite this, further information about the epidemiology, prognosis and potential therapies are required to better manage and diagnose PPCM in women with signs and symptoms of heart failure.",
author = "Richard Sheppard and Navin Rajagopalan and Jordan Safirstein and Joan Briller",
year = "2014",
month = "1",
day = "1",
doi = "10.2217/fca.14.23",
language = "English (US)",
volume = "10",
pages = "435--447",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "3",

}

An update on treatments and outcomes in peripartum cardiomyopathy. / Sheppard, Richard; Rajagopalan, Navin; Safirstein, Jordan; Briller, Joan.

In: Future Cardiology, Vol. 10, No. 3, 01.01.2014, p. 435-447.

Research output: Contribution to journalReview article

TY - JOUR

T1 - An update on treatments and outcomes in peripartum cardiomyopathy

AU - Sheppard, Richard

AU - Rajagopalan, Navin

AU - Safirstein, Jordan

AU - Briller, Joan

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Peripartum cardiomyopathy (PPCM) is a well-established complication of pregnancy. Criteria include heart failure that presents with reduced left ventricular function, signs and symptoms of heart failure either late in pregnancy or early in the postpartum period. The incidence varies widely depending geography and ethnicity. The pathophysiology of PPCM is still an area of active investigation, but includes immune and inflammatory mechanisms, which are the subject of several investigations. Therapies for chronic heart failure from PPCM are similar to those patients with nonischemic cardiomyopathy from different etiologies, however novel therapies may include bromocriptine, pentoxifylline or other potential therapies influencing the immune system. The need for implantable defibrillators, left ventricular assist devices and cardiac transplant in women with PPCM is rare, and prognosis is better than other forms of nonischemic cardiomyopathy. Despite this, further information about the epidemiology, prognosis and potential therapies are required to better manage and diagnose PPCM in women with signs and symptoms of heart failure.

AB - Peripartum cardiomyopathy (PPCM) is a well-established complication of pregnancy. Criteria include heart failure that presents with reduced left ventricular function, signs and symptoms of heart failure either late in pregnancy or early in the postpartum period. The incidence varies widely depending geography and ethnicity. The pathophysiology of PPCM is still an area of active investigation, but includes immune and inflammatory mechanisms, which are the subject of several investigations. Therapies for chronic heart failure from PPCM are similar to those patients with nonischemic cardiomyopathy from different etiologies, however novel therapies may include bromocriptine, pentoxifylline or other potential therapies influencing the immune system. The need for implantable defibrillators, left ventricular assist devices and cardiac transplant in women with PPCM is rare, and prognosis is better than other forms of nonischemic cardiomyopathy. Despite this, further information about the epidemiology, prognosis and potential therapies are required to better manage and diagnose PPCM in women with signs and symptoms of heart failure.

UR - http://www.scopus.com/inward/record.url?scp=84903733047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903733047&partnerID=8YFLogxK

U2 - 10.2217/fca.14.23

DO - 10.2217/fca.14.23

M3 - Review article

VL - 10

SP - 435

EP - 447

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 3

ER -